Leaders in Medicine and Science Celebrate Innovation at the Feinstein Institutes During Two Annual Academic Events
'The Feinstein Institutes' commitment to translational research was evident throughout this two-day celebration,' said Bettie M. Steinberg, PhD, interim dean of the Elmezzi Graduate School of Molecular Medicine and professor in the Feinstein Institutes Institute of Molecular Medicine. 'The symposium highlighted cutting-edge discoveries poised to move from the lab to the clinic, while the Elmezzi graduates represent the next generation of scientists dedicated to turning scientific advancements into tangible therapies.'
Meeting of minds at the Feinstein Academy of Scholars Symposium
Members of the Academy include recipients of honorary doctoral degrees from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers, recipients of the Cerami, Ross and Advancing Women in Science and Medicine (AWSM) prizes, and researchers from the Feinstein Institutes.
This year's featured keynote speakers included:
Tobias Janowitz, MD, PhD, associate professor and Cancer Center Program Leader at Cold Spring Harbor Laboratory, provided an overview of the current research on systemic signaling in paraneoplasia, emphasizing the importance of this area of study.
Lopa Mishra, MD, co-director and professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Susan and Herman Merinoff Distinguished Chair in Translational Medicine, explained how specific environmental toxins contribute to liver cancer and outlined methods to selectively target these cancer cells.
Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine, spoke about examining the role of immune dysregulation in the pathogenesis of post-acute infection syndrome.
Douglas F. Nixon, MD, PhD, Karches Family Professor in Translational Research and director and professor, Institute of Translational Research at the Feinstein Institutes, spoke about human endogenous retroviruses (HERVs) are part of our non-coding DNA and that our own genomes can impact our health and disease.
Max Brenner, MD, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, spoke about an Elmezzi scholar's scientific journey stemming from the classroom to the clinic and the lab.
Linda Van Aelst, PhD, professor at Cold Spring Harbor Laboratory, discussed the intricate involvement of Rho regulators in synapse formation and dysfunction.
Celebrating the future of medical research
On May 22, two clinicians were conferred their PhD during the Elmezzi Graduate School of Molecular Medicine graduation. This unique PhD program is for physicians (MDs) who wish to pursue careers in biomedical research. During the program, Elmezzi students conduct research in Feinstein Institutes laboratories to advance medical research and pursue new therapeutic approaches and diagnostic tools. The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from the Thomas and Jeanne Elmezzi Foundation.
Two honorary degrees were bestowed at the Elmezzi commencement. The first to Dr. Iwasaki for her research on immune defense against viruses at mucosal surfaces, and to Dr. Rothblatt for her contributions to new treatments for rare diseases and advances in organ transplants. In addition, she was the creator of the satellite radio company SiriusXM. This year's graduates include:
Willians Tambo Ayol, MD, investigated the role of microvascular dysfunction in cognitive impairment and dementia, and explored the therapeutic potential of the diving reflex's protective mechanisms against cerebral hypoperfusion.
Santhoshi Poonacha Palandira, MBBS, MS, MCh, applied optogenetics to neuromodulate brainstem nuclei to regulate inflammation. She also identified celiac-superior mesenteric ganglion complex in the abdomen and identified it as a new therapeutic target for noninvasive bioelectronic therapies to treat inflammation with a translational potential.
'Physician-scientists produce the innovations and discoveries that make a healthier world,' said Kevin J. Tracey, MD, president and CEO of Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. 'Elmezzi graduates are committed to career paths that will lead to new therapies and diagnostics.'
To find out more about the Elmezzi Graduate School of Molecular Medicine and its programs, click here.
About The Elmezzi Graduate School of Molecular Medicine:
The Elmezzi Graduate School of Molecular Medicine at Northwell Health offers MDs an accelerated PhD three-year program emphasizing translational research. Its mission is to provide academic training for physicians to discover and understand the causes of human diseases and to rapidly and effectively translate this information into diagnostic and therapeutic solutions. The program started in 1994 and is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation. To date, more than 50 physician-scientists have graduated from the prestigious program. The Elmezzi School of Molecular Medicine is accredited by the WASC Senior College and University Commission (WSCUC). For more information, click here.
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
2 days ago
- Washington Post
It's not your imagination. Your period may be making your depression worse.
One in six women in the United States has depression, according to Centers for Disease Control and Prevention data based on a self-reported questionnaire. And new research seems to confirm what many suspect — the symptoms often can get worse just before your period. It's called premenstrual exacerbation (PME) of depression, and as many as 58 percent of people with depression who menstruate might have it, studies suggest. 'It could be they're experiencing premenstrual worsening of depressed sadness, or feelings of guilt or worthlessness, or loss of interest or pleasure,' said Jaclyn Ross, a licensed clinical psychologist at the Chicago Premenstrual Disorders Clinic. Most recently, a study published in BMJ Mental Health found that mood ratings were lowest from three days before until two days after their period in women with depression who tracked their symptoms. Premenstrual exacerbation of depression differs from the more commonly known premenstrual syndrome (PMS), which is characterized by physical symptoms such as aches, bloating and cramping, and emotional symptoms such as anxiety and mood swings, leading up to your period. However, both PME and PMS fall under the same 'umbrella of premenstrual emotional symptoms,' said Tory Eisenlohr-Moul, an associate professor of psychiatry and psychology at the University of Illinois Chicago College of Medicine, and a co-author of a study about PME published in the journal Biological Psychiatry in May. Premenstrual exacerbation of depression is easily confused with premenstrual dysphoric disorder (PMDD), a mood disorder that can also cause depression, anger and irritability around the middle of the menstrual cycle. The latter has been better-studied: In 2013, PMDD was included in the Diagnostic and Statistical Manual of Mental Disorders, or DSM-5, the reference book used by clinicians to define mental health conditions. The more important distinction, experts said, isn't so much symptom type or severity (both PME of depression and PMDD can be severe), but 'what happens during the follicular phase of the cycle,' Susan Kornstein, a professor of psychiatry and obstetrics & gynecology at Virginia Commonwealth University, wrote in an email. With PMDD, a person probably has no depressive symptoms in that follicular phase, which lasts from the first day of the new cycle until ovulation. Then, 'the symptoms turn on like a light switch,' Ross said, and, within a few days of menstruation, 'they turn off like a light switch.' On the other hand, PME 'is more like a dial,' she said. Because there's a preexisting condition — in this case, depression — 'symptoms are there all the time, but they turn up.' Official diagnostic criteria for PME don't exist — patients are diagnosed and treated based on the underlying disorder. 'Basically, PMDD was the cleaner alternative to create the diagnosis,' Eisenlohr-Moul said, 'but we know we have a lot of work to do to be more inclusive for people with messier symptom patterns.' Unlike PMDD, she said, PME 'is harder to see because you also have background things going on.' Just to make it all more complicated, Eisenlohr-Moul pointed out that a person might have PMDD then eventually develop chronic PME of depression. It's also possible to have both conditions, or symptoms that resemble PME but are something else entirely. Formally recognizing PME as a separate condition is a matter of some debate among experts, but its inclusion could open up more treatment options for patients, Eisenlohr-Moul pointed out. People with other psychiatric diagnoses may have symptoms that are exacerbated by the menstrual cycle. It's possible to experience PME 'of pretty much any mental health disorder,' Ross said, including obsessive-compulsive disorder, eating disorders and generalized anxiety disorder. With PME of depression, your symptoms tend to get worse during the luteal phase, seven to 14 days before your period, Eisenlohr-Moul said. You might feel intensely sad, or more fatigued or withdrawn than you do at other times in your cycle, according to the International Association for Premenstrual Disorders (IAPMD), a nonprofit that advocates for people with premenstrual conditions. Thoughts of self-harm and suicidality can also increase during this time. Symptoms usually return to their baseline after you get your period. The exact timing of symptoms can vary from month to month, though, 'which is so frustrating for scientists, clinicians and patients,' Ross noted. 'We want it to be neat and tidy.' Not all women with depression experience worse symptoms before their period. Although researchers have found you can have symptoms even if you're taking antidepressants. A common misconception is that PME is caused by hormonal imbalances. 'It's actually that you have an abnormal brain sensitivity to normal hormone fluctuations that happen across the menstrual cycle,' Ross said. 'The way I think of it is that your brain is allergic to your menstrual cycle.' Track your symptoms If your depression seems worse leading up to your period, start by writing down how you feel daily over the course of two menstrual cycles to look for patterns. Reporting back on symptoms from memory 'is not always reliable,' Kornstein said, 'which is why prospective daily charting is needed.' Eisenlohr-Moul recommended downloading the free symptom tracker worksheet on the IAPMD website. Connect with a provider who listens Your doctor should believe you if you tell them you're experiencing heightened depression around your period, then help monitor those symptoms to understand the impact they're having on your life. 'If a provider dismisses you or turns you away, find a new provider,' Eisenlohr-Moul said. Consider working with a therapist Ross recommended acceptance and commitment therapy (ACT), dialectical behavior therapy (DBT) or cognitive behavioral therapy (CBT) — 'all three of those contain elements that can be really useful for managing premenstrual symptoms.' Ideally, your therapist will work with you on tailoring coping skills to your cycle, she said, so you're better equipped on days you're most vulnerable. Ask about medication options Serotonin reuptake inhibitors (SSRIs) and birth control pills that contain drospirenone or ethinyl estradiol are approved to treat PPMD, but PME may require a different approach. Still, 'the frontline treatment for premenstrual emotional symptoms is SSRIs,' Ross said, so this can be 'a good place for people to start.' Some clinicians might prescribe an increased dose for high-symptom days. Oral contraceptives are also 'worth exploring as a potential treatment option' for PME, Ross added, 'although there's not a one-size-fits-all approach here.' (On the other hand, if you've already been taking oral contraceptives and are having exacerbated symptoms around your period, sometimes changing them may help, said Veerle Bergink, a professor in psychiatry and the director of Mount Sinai's Women's Mental Health Center.) On good days, follow a routine Sleep, diet and exercise aren't going to cure depression, experts stressed. (And implying that 'can be really discouraging and invalidating for people,' Ross noted.) But establishing positive lifestyle strategies might make harder days easier to manage. 'One of the things I hear patients talk about a lot is going into 'rotting' mode in bed,' Ross said. 'Maybe when I feel good in my follicular phase, maybe I run every day. That's not going to happen during the high-symptom phase, but could I still go for a 20- minute walk?' Catherine Monk, a clinical psychologist and the Diana Vagelos Professor of Women's Mental Health in obstetrics & gynecology at Columbia University, suggested making a list of calming activities you love, then trying to do at least one on high-symptom days: 'Not that it's going to make you feel fantastic, but it can help.' Establish a safety plan While not everyone with PMDD or PME of depression will have life-threatening thoughts, studies show that women with premenstrual disorders may have higher risk of self-harm. In a 2024 study published in the American Journal of Psychiatry, Ross, Eisenlohr-Moul and other researchers found that the menstrual cycle could worsen suicidal ideation and planning among psychiatric outpatients who'd had suicidal thoughts in the month prior. If your symptoms become severe, work with your medical team to put a safety plan into action on high-symptom days, Monk said. Most importantly, no one experiencing depression should suffer in silence, they said. Regardless of whether your depression is chronic, then gets worse around your period, or only appears leading up to menstruation, help is available. 'We don't want to contribute to this idea that all women have PMS, or all women with depression are depressed because of their hormones,' Eisenlohr-Moul said. 'Having said that, if you are a woman with depression, you are at greater risk of having these hormone sensitivity changes, and it makes sense to track and see if you are one of those people.' If you or someone you know needs help, call 988 or visit
Boston Globe
4 days ago
- Boston Globe
Costco will not sell abortion pills after pressure from conservatives
Despite lawsuits and letters pleading to lawmakers, their campaign to thwart access to abortion pills has otherwise been slow-moving. Patients can still access medication abortion in all 50 states, even those where the procedure is illegal, because of laws allowing the pills to be remotely prescribed and mailed. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up In a statement Thursday, Costco said the decision was 'based on the lack of demand from our members and other patients.' The company did not answer further questions from The Washington Post about the influence of outside groups. Advertisement This month, Costco officials said they would not look to become certified to dispense mifepristone after a coalition of religious and conservative financial groups approached them ahead of formally requesting action on the issue, according to people familiar with the conversations. The company's decision was 'a step in the right direction,' said Michael Ross, an attorney on the corporate engagement team of the Alliance Defending Freedom, a Christian conservative legal organization. ADF was a leader in the charge to keep mifepristone off Costco's shelves. Advertisement 'It doesn't make sense as a fiduciary matter for these companies to be injecting themselves into this political controversy,' Ross said. For two decades, the Food and Drug Administration, which in 2000 approved mifepristone for use through 10 weeks of pregnancy, required that the drug be picked up in person, a mandate abortion rights advocates saw as a hurdle in accessing the procedure. In 2021, the agency halted the in-person requirement. Then, after the Supreme Court in 2022 struck down the constitutional right to an abortion, triggering abortion bans across the country, lawmakers in blue states passed 'shield' laws designed to protect abortion providers from prosecutions. Those measures, active in eight states, allow providers to legally prescribe abortion pills regardless of where a patient lives. The battle over whether mifepristone would be sold in retail pharmacies began in March 2024, when CVS and Walgreens received FDA certification to sell the pill. Four months later, New York City Comptroller Brad Lander sent letters to a handful of other household-name pharmacies, urging them to follow in the footsteps of CVS and Walgreens. In his letters to Costco, Walmart, Kroger, Albertsons and McKesson, Landers reminded the companies that New York City's pension system owned shares in them. The shares in Costco alone at the time were valued at $443.9 million. Getting certified to dispense the pill, Lander wrote to Costco CEO Ron Vachris, 'aligns with both long-term shareholder interests and women's health care needs.' Conservative opponents swiftly disagreed. A coalition of groups and individual investors sent letters to the same five companies. At the time, their stock in Costco was worth about $56 million. Thousands of Costco members and investors also signed a petition saying they did not want the company to sell mifepristone, an effort spearheaded by Inspire Investing, a Christian financial firm that is part of the coalition. Advertisement As pressure from investors mounted, Costco indicated it did not plan to become certified to sell mifepristone, citing customer interest. Tim Schwarzenberger, Inspire Investing's director of corporate engagement, said Costco's choice 'protects its brand, serves families, and keeps the company focused on what it does best.' 'By recognizing there was no customer demand and avoiding an ideological path, Costco steered clear of moral, legal, and business risks while staying true to its mission,' he said in a statement. As of Thursday, it was unclear how the other companies would act. Kroger told The Post that it was still reviewing the FDA's requirements to dispense mifepristone. Walmart declined to comment. McKesson, which includes the Health Mart franchise, and Albertsons did not immediately respond to requests for comment. Ross, the ADF attorney, said the coalition had also filed a shareholder proposal to CVS, which has been selling mifepristone for more than a year, and plans to do so for other companies. 'We're hoping to build on this win,' he said.
Business Wire
30-07-2025
- Business Wire
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended June 30, 2025, driven by continued double-digit year-over-year revenue growth in key products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Total revenues in the second quarter of 2025 grew 12 percent year-over-year to a record $798.6 million, compared to $714.9 million in the second quarter of 2024. 'Our second quarter yet again produced record-setting results driven by the strength of our foundational commercial business,' said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. 'We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth, starting with data from the TETON 2 study of nebulized treprostinil in idiopathic pulmonary fibrosis expected in September that could fundamentally improve options for patients with this progressive, deadly disease with few treatments available. 'Equally, our strong financial position, confidence in these upcoming catalysts, and belief in our share price potential has led our Board of Directors to authorize up to $1 billion in share repurchases, affirming our commitment to a robust and balanced capital allocation philosophy.' Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, 'We're proud of the continued record performance for Tyvaso DPI, a best-in-class treprostinil dry powder inhaler that allows the flexibility of one breath per cartridge, four times a day, with low inspiratory effort. Further, no other commercially available treprostinil dry powder inhaler has been clinically studied with published data at higher doses 1,2 or prescribed by more physicians to more patients than Tyvaso DPI. 'We expect continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.' Second Quarter 2025 Financial Results Key financial highlights include (dollars in millions, except per share data): Revenues The table below presents the components of total revenues (dollars in millions): (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity ® Pump. Expand Total Tyvaso revenues grew by 18 percent to $469.6 million in the second quarter of 2025, compared to $398.2 million in the second quarter of 2024. The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold of $54.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in Tyvaso DPI quantities sold was primarily due to continued growth in the number of patients following the product's launch, including growth in utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to a lesser extent, increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act (IRA). The growth in Nebulized Tyvaso revenues resulted primarily from an increase in quantities sold and, to a lesser extent, a price increase. The growth in Orenitram revenues resulted primarily from an increase in quantities sold of $10.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in quantities sold was driven, at least in part, by increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the IRA. The table below presents the breakdown of total revenues between the United States and rest-of-world (ROW) (in millions): (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity Pump. Expand Expenses Cost of sales. The table below summarizes cost of sales by major category (dollars in millions): (1) See Share-based compensation below. Expand Cost of sales, excluding share-based compensation. Cost of sales for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to an increase in: (1) royalty expense resulting from a growth in revenues; and (2) reserve expense resulting from increased production. Research and development. The table below summarizes the nature of research and development expense by major expense category (dollars in millions): (1) External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before FDA approval of the relevant product. (2) Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before FDA approval, and internal facilities-related expenses, including depreciation, related to research and development activities. (3) See Share-based compensation below. (4) Other primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products and adjustments to the fair value of our contingent consideration obligations. Expand Research and development, excluding share-based compensation. Research and development expense for the three months ended June 30, 2025 decreased as compared to the same period in 2024, primarily due to $36.0 million in upfront non-refundable license payments for drug delivery device technologies in 2024, partially offset by: (1) increased expenditures in 2025 related to manufactured organ and organ alternative projects; and (2) a $5.0 million milestone payment made in 2025 for drug delivery device technologies. Selling, general, and administrative. The table below summarizes selling, general, and administrative expense by major category (dollars in millions): (1) Excluding impairment of PP&E. See Impairment of PP&E section below. (2) Calculation is not meaningful. (3) See Share-based compensation below. Expand General and administrative, excluding impairment of PP&E and share-based compensation. General and administrative expense for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to: (1) personnel expense due to growth in headcount; and (2) legal expenses related to litigation matters. Impairment of PP&E. During the three months ended June 30, 2025, we recorded a $21.7 million impairment charge to write down the carrying value of certain PP&E. Share-based compensation. The table below summarizes share-based compensation expense by major category (dollars in millions): The decrease in share-based compensation expense for the three months ended June 30, 2025, as compared to the same period in 2024, was primarily due to a decrease in STAP expense, as all remaining STAP awards were exercised during the first quarter of 2025. Income tax expense. Income tax expense for the three months ended June 30, 2025 and 2024 was $98.9 million and $77.2 million, respectively. Our effective income tax rate (ETR) for the three months ended June 30, 2025 and 2024 was 24 percent and 22 percent, respectively. Our ETR for the three months ended June 30, 2025 increased compared to our ETR for the three months ended June 30, 2024, primarily due to a decrease in excess tax benefits from share-based compensation. Webcast We will host a webcast to discuss our second quarter 2025 financial results on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast can be accessed live via our website at An investor presentation is available now, and after the webcast a replay of the webcast will also be available, at the same location on our website. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: Forward-Looking Statements Statements included in this press release that are not historical in nature are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our share repurchase program, the anticipated timing and outcome of the TETON 2 and TETON 1 clinical trials of Nebulized Tyvaso in idiopathic pulmonary fibrosis, including potential for these studies to improve options for patients with this disease; the anticipated readout of the ADVANCE OUTCOMES clinical trial of ralinepag; our near- to medium-term catalysts positioned for sustained long-term growth; our expectation of continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 30, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason. ORENITRAM, REMODULIN, REMUNITY, TYVASO, TYVASO DPI, and UNITUXIN are registered trademarks of United Therapeutics Corporation and/or its subsidiaries. ADCIRCA is a registered trademark of Eli Lilly and Company. SELECTED CONSOLIDATED BALANCE SHEET DATA (Unaudited, in millions) June 30, 2 025 Cash, cash equivalents, and marketable investments $ 4,966.4 Total assets 7,908.0 Total liabilities 734.4 Total stockholders' equity 7,173.6 Expand Category: Earnings
